LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Blueprint Medicines Corp

Suletud

SektorTervishoid

97.67 -1.84

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

97.3

Max

100.06

Põhinäitajad

By Trading Economics

Sissetulek

50M

496K

Müük

3M

149M

Aktsiakasum

-0.294

Kasumimarginaal

0.332

Töötajad

682

EBITDA

-14M

-41M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+28.24% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

763M

6.5B

Eelmine avamishind

99.51

Eelmine sulgemishind

97.67

Uudiste sentiment

By Acuity

67%

33%

333 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Blueprint Medicines Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. mai 2025, 23:20 UTC

Tulu

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13. mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13. mai 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. mai 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13. mai 2025, 23:24 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

13. mai 2025, 23:24 UTC

Market Talk
Tulu

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13. mai 2025, 22:58 UTC

Tulu

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13. mai 2025, 22:58 UTC

Tulu

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13. mai 2025, 22:58 UTC

Tulu

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13. mai 2025, 22:58 UTC

Tulu

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13. mai 2025, 22:38 UTC

Tulu

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13. mai 2025, 22:38 UTC

Tulu

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13. mai 2025, 22:37 UTC

Tulu

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13. mai 2025, 22:36 UTC

Tulu

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13. mai 2025, 22:35 UTC

Tulu

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13. mai 2025, 22:34 UTC

Tulu

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13. mai 2025, 22:33 UTC

Tulu

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13. mai 2025, 22:33 UTC

Tulu

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13. mai 2025, 22:33 UTC

Tulu

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13. mai 2025, 22:30 UTC

Tulu

Aristocrat Interim Dividend 44 Australian Cents/Share

13. mai 2025, 22:30 UTC

Tulu

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13. mai 2025, 22:29 UTC

Tulu

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13. mai 2025, 22:28 UTC

Tulu

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13. mai 2025, 21:15 UTC

Tulu

Nu Holdings 1Q Rev $3.2B >NU

13. mai 2025, 21:03 UTC

Peamised uudised

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13. mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. mai 2025, 20:32 UTC

Tulu

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13. mai 2025, 20:31 UTC

Tulu

Alcon 1Q Sales $2.45B >ALC.EB

13. mai 2025, 20:30 UTC

Tulu

Alcon 1Q Rev $2.47B >ALC.EB

13. mai 2025, 20:30 UTC

Tulu

Alcon 1Q EPS 70c >ALC.EB

Võrdlus sarnastega

Hinnamuutus

Blueprint Medicines Corp Prognoos

Hinnasiht

By TipRanks

28.24% tõus

12 kuu keskmine prognoos

Keskmine 127.47 USD  28.24%

Kõrge 155 USD

Madal 93 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Blueprint Medicines Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

12

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

87.66 / 99.25Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Sentiment

By Acuity

333 / 382 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.